RLMD
Relmada Therapeutics, Inc.
Biotechnology
Market Cap$545M
5Y Perf.-22.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RLMD vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
RLMD vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RLMD | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $545M | $1712.35T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-57M | $-168M |
| Total Debt | $0.00 | $22M |
| Cash & Equiv. | $3M | $194M |
RLMD vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RLMD
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Relmada Therapeutic… (RLMD) | 100 | 77.1 | -22.9% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RLMD vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RLMD leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
RLMD
Relmada Therapeutics, Inc.
The Growth Play
RLMD carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 45.3%
- 312.8% 10Y total return vs DBVT's -87.0%
- -60.5% revenue growth vs DBVT's -100.0%
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.26
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RLMD | -60.5% revenue growth vs DBVT's -100.0% |
| Quality / Margins | RLMD | 1.5% margin vs DBVT's 0.3% |
| Stability / Safety | DBVT | Beta 1.26 vs RLMD's 1.40 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RLMD | +20.6% vs DBVT's +110.4% |
| Efficiency (ROA) | DBVT | -89.0% ROA vs RLMD's -145.6% |
RLMD vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGRLMD
RLMDRelmada Therapeutics,…
1leads
DBVTDBV Technologies S.A.
2leads
6 Total Categories
CATEGORYLEADERvs RLMDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DBVT4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
RLMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RLMD and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | RLMDRelmada Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$59M | -$112M |
| Net IncomeAfter-tax profit | -$57M | -$168M |
| Free Cash FlowCash after capex | $0 | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +53.2% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — RLMD and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | RLMDRelmada Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $545M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $541M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -5.12x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 3.39x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — RLMD and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
DBVT leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
DBVT delivers a -130.2% return on equity — every $100 of shareholder capital generates $-130 in annual profit, vs $-171 for RLMD. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs RLMD's 3/9, reflecting mixed financial health.
| Metric | RLMDRelmada Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -170.8% | -130.2% |
| ROA (TTM)Return on assets | -145.6% | -89.0% |
| ROICReturn on invested capital | -77.3% | — |
| ROCEReturn on capital employed | -96.0% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | -$3M | -$172M |
| Cash & Equiv.Liquid assets | $3M | $194M |
| Total DebtShort + long-term debt | $0 | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
DBVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
RLMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RLMD five years ago would be worth $10,220 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, RLMD leads with a +2060.5% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors RLMD at 103.2% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | RLMDRelmada Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +70.0% | +4.9% |
| 1-Year ReturnPast 12 months | +2060.5% | +110.4% |
| 3-Year ReturnCumulative with dividends | +739.5% | +19.7% |
| 5-Year ReturnCumulative with dividends | +2.2% | -69.1% |
| 10-Year ReturnCumulative with dividends | +312.8% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +103.2% | +6.2% |
RLMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RLMD and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than RLMD's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RLMD currently trades 92.9% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RLMDRelmada Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.40x | 1.26x |
| 52-Week HighHighest price in past year | $8.00 | $26.18 |
| 52-Week LowLowest price in past year | $0.32 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +92.9% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 64.0 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 2.0M | 252K |
Evenly matched — RLMD and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RLMD as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 21.1% for RLMD (target: $9).
| Metric | RLMDRelmada Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $46.33 |
| # AnalystsCovering analysts | 8 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RLMD leads in 1 (Total Returns). 2 tied.
Best OverallDBV Technologies S.A. (DBVT)Leads 2 of 6 categories
Loading custom metrics...
RLMD vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RLMD or DBVT a better buy right now?
Analysts rate Relmada Therapeutics, Inc.
(RLMD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RLMD or DBVT?
Over the past 5 years, Relmada Therapeutics, Inc.
(RLMD) delivered a total return of +2. 2%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: RLMD returned +312. 8% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RLMD or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Relmada Therapeutics, Inc. 's 1. 40β — meaning RLMD is approximately 11% more volatile than DBVT relative to the S&P 500.
04Which is growing faster — RLMD or DBVT?
On earnings-per-share growth, the picture is similar: Relmada Therapeutics, Inc.
grew EPS 45. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RLMD or DBVT?
Relmada Therapeutics, Inc.
(RLMD) is the more profitable company, earning 0. 0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RLMD leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — RLMD leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RLMD or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RLMD or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Relmada Therapeutics, Inc.
(RLMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+312. 8% 10Y return). Both have compounded well over 10 years (RLMD: +312. 8%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RLMD and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.